Intranasal beclomethasone inhibits antigen-induced nasal hyperresponsiveness to histamine

J Allergy Clin Immunol. 1992 Sep;90(3 Pt 1):373-6. doi: 10.1016/s0091-6749(05)80017-x.

Abstract

To determine whether intranasal steroid treatment inhibits the increased sensitivity to histamine that occurs 24 hours after nasal antigen challenge, 12 allergic volunteers were entered into a double-blind study comparing placebo or 164 micrograms of beclomethasone dipropionate twice a day for 7 days. Beclomethasone dipropionate partially reduced the early mediator response to antigen and the influx of eosinophils 24 hours later. Comparing the initial histamine challenge with that done 24 hours after antigen with the subjects on placebo, there was a significant increase in sneezes, TAME-esterase activity, and albumin. Pretreatment with intranasal beclomethasone dipropionate resulted in a reduced response to histamine 24 hours after antigen challenge. A positive correlation occurred between the number of eosinophils in the lavage before histamine challenge and the level of TAME-esterase activity (rs = 0.67, p = 0.03) during the histamine challenge that followed antigen with the subjects on placebo. We thus confirmed the increase in nonspecific nasal airway responsiveness 24 hours after antigen challenge, with a concomitant increase in eosinophils, and demonstrate its inhibition by pretreatment with intranasal steroids.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Intranasal
  • Antigens / immunology*
  • Beclomethasone / administration & dosage
  • Beclomethasone / pharmacology*
  • Eosinophils / drug effects
  • Histamine / pharmacology*
  • Humans
  • Nasal Mucosa / drug effects*
  • Nasal Mucosa / immunology
  • Peptide Hydrolases / analysis

Substances

  • Antigens
  • Histamine
  • Peptide Hydrolases
  • tosylarginine methyl ester hydrolase
  • Beclomethasone